8-10 years ahead' of field in oral delivery, senior execs say Novo is becoming a GLP-1 company

At a media event at Novo Nordisk (NOV: N) headquarters in Copenhagen, the Danish diabetes giant provided insights into its clinical and commercial strategies on Wednesday.

While chief executive Lars Fruergaard Jørgensen said the firm was “more and more becoming a GLP-1 based company," chief scientific officer Mads Krogsgaard Thomsen said Novo was “maybe 8-10 years ahead of competition in oral GLP-1.”

The firm has suffered from declining sales in parts of its key revenue-generating insulin portfolio recently, but has a promising story to tell about the potential for new forms of diabetes management, including the first oral biologic, as well as the potential to play in the growing market for obesity therapies.